Summary:
- Novavax, a COVID-19 vaccine manufacturer, has halted its vaccine projects and announced significant job cuts due to declining demand for COVID-19 vaccines.
- The company is facing financial challenges as the global vaccination rollout slows down, with many countries having already achieved high vaccination rates.
- Novavax's decision reflects the changing landscape of the COVID-19 pandemic, where the focus is shifting from mass vaccination campaigns to targeted booster shots and treatments.